Cargando…
P1083: BRENTUXIMAB VEDOTIN, ETOPOSIDE, SOLUMEDROL, HIGH DOSE ARA-C & PLATINUM FOLLOWED BY HDT & APBSCT FOR REFRACTORY/RELAPSED HODGKIN LYMPHOMA PATIENTS: LONG-TERM RESULTS OF THE GELTAMO GROUP BRESHAP STUDY
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429181/ http://dx.doi.org/10.1097/01.HS9.0000847200.09935.17 |
| _version_ | 1784779357906010112 |
|---|---|
| author | Garcia-Sanz, R. Martínez, C. De la Cruz, F. González, A. P. Rodríguez, A. Sánchez-González, B. Domingo-Domenech, E. Moreno, M. López, J. Piñana, J. L. Bastos, M. Canales, M. Gutiérrez, A. Rodríguez-Salazar, M. J. Navarro, A. Sureda, A. |
| author_facet | Garcia-Sanz, R. Martínez, C. De la Cruz, F. González, A. P. Rodríguez, A. Sánchez-González, B. Domingo-Domenech, E. Moreno, M. López, J. Piñana, J. L. Bastos, M. Canales, M. Gutiérrez, A. Rodríguez-Salazar, M. J. Navarro, A. Sureda, A. |
| author_sort | Garcia-Sanz, R. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429181 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94291812022-08-31 P1083: BRENTUXIMAB VEDOTIN, ETOPOSIDE, SOLUMEDROL, HIGH DOSE ARA-C & PLATINUM FOLLOWED BY HDT & APBSCT FOR REFRACTORY/RELAPSED HODGKIN LYMPHOMA PATIENTS: LONG-TERM RESULTS OF THE GELTAMO GROUP BRESHAP STUDY Garcia-Sanz, R. Martínez, C. De la Cruz, F. González, A. P. Rodríguez, A. Sánchez-González, B. Domingo-Domenech, E. Moreno, M. López, J. Piñana, J. L. Bastos, M. Canales, M. Gutiérrez, A. Rodríguez-Salazar, M. J. Navarro, A. Sureda, A. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429181/ http://dx.doi.org/10.1097/01.HS9.0000847200.09935.17 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Garcia-Sanz, R. Martínez, C. De la Cruz, F. González, A. P. Rodríguez, A. Sánchez-González, B. Domingo-Domenech, E. Moreno, M. López, J. Piñana, J. L. Bastos, M. Canales, M. Gutiérrez, A. Rodríguez-Salazar, M. J. Navarro, A. Sureda, A. P1083: BRENTUXIMAB VEDOTIN, ETOPOSIDE, SOLUMEDROL, HIGH DOSE ARA-C & PLATINUM FOLLOWED BY HDT & APBSCT FOR REFRACTORY/RELAPSED HODGKIN LYMPHOMA PATIENTS: LONG-TERM RESULTS OF THE GELTAMO GROUP BRESHAP STUDY |
| title | P1083: BRENTUXIMAB VEDOTIN, ETOPOSIDE, SOLUMEDROL, HIGH DOSE ARA-C & PLATINUM FOLLOWED BY HDT & APBSCT FOR REFRACTORY/RELAPSED HODGKIN LYMPHOMA PATIENTS: LONG-TERM RESULTS OF THE GELTAMO GROUP BRESHAP STUDY |
| title_full | P1083: BRENTUXIMAB VEDOTIN, ETOPOSIDE, SOLUMEDROL, HIGH DOSE ARA-C & PLATINUM FOLLOWED BY HDT & APBSCT FOR REFRACTORY/RELAPSED HODGKIN LYMPHOMA PATIENTS: LONG-TERM RESULTS OF THE GELTAMO GROUP BRESHAP STUDY |
| title_fullStr | P1083: BRENTUXIMAB VEDOTIN, ETOPOSIDE, SOLUMEDROL, HIGH DOSE ARA-C & PLATINUM FOLLOWED BY HDT & APBSCT FOR REFRACTORY/RELAPSED HODGKIN LYMPHOMA PATIENTS: LONG-TERM RESULTS OF THE GELTAMO GROUP BRESHAP STUDY |
| title_full_unstemmed | P1083: BRENTUXIMAB VEDOTIN, ETOPOSIDE, SOLUMEDROL, HIGH DOSE ARA-C & PLATINUM FOLLOWED BY HDT & APBSCT FOR REFRACTORY/RELAPSED HODGKIN LYMPHOMA PATIENTS: LONG-TERM RESULTS OF THE GELTAMO GROUP BRESHAP STUDY |
| title_short | P1083: BRENTUXIMAB VEDOTIN, ETOPOSIDE, SOLUMEDROL, HIGH DOSE ARA-C & PLATINUM FOLLOWED BY HDT & APBSCT FOR REFRACTORY/RELAPSED HODGKIN LYMPHOMA PATIENTS: LONG-TERM RESULTS OF THE GELTAMO GROUP BRESHAP STUDY |
| title_sort | p1083: brentuximab vedotin, etoposide, solumedrol, high dose ara-c & platinum followed by hdt & apbsct for refractory/relapsed hodgkin lymphoma patients: long-term results of the geltamo group breshap study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429181/ http://dx.doi.org/10.1097/01.HS9.0000847200.09935.17 |
| work_keys_str_mv | AT garciasanzr p1083brentuximabvedotinetoposidesolumedrolhighdosearacplatinumfollowedbyhdtapbsctforrefractoryrelapsedhodgkinlymphomapatientslongtermresultsofthegeltamogroupbreshapstudy AT martinezc p1083brentuximabvedotinetoposidesolumedrolhighdosearacplatinumfollowedbyhdtapbsctforrefractoryrelapsedhodgkinlymphomapatientslongtermresultsofthegeltamogroupbreshapstudy AT delacruzf p1083brentuximabvedotinetoposidesolumedrolhighdosearacplatinumfollowedbyhdtapbsctforrefractoryrelapsedhodgkinlymphomapatientslongtermresultsofthegeltamogroupbreshapstudy AT gonzalezap p1083brentuximabvedotinetoposidesolumedrolhighdosearacplatinumfollowedbyhdtapbsctforrefractoryrelapsedhodgkinlymphomapatientslongtermresultsofthegeltamogroupbreshapstudy AT rodrigueza p1083brentuximabvedotinetoposidesolumedrolhighdosearacplatinumfollowedbyhdtapbsctforrefractoryrelapsedhodgkinlymphomapatientslongtermresultsofthegeltamogroupbreshapstudy AT sanchezgonzalezb p1083brentuximabvedotinetoposidesolumedrolhighdosearacplatinumfollowedbyhdtapbsctforrefractoryrelapsedhodgkinlymphomapatientslongtermresultsofthegeltamogroupbreshapstudy AT domingodomeneche p1083brentuximabvedotinetoposidesolumedrolhighdosearacplatinumfollowedbyhdtapbsctforrefractoryrelapsedhodgkinlymphomapatientslongtermresultsofthegeltamogroupbreshapstudy AT morenom p1083brentuximabvedotinetoposidesolumedrolhighdosearacplatinumfollowedbyhdtapbsctforrefractoryrelapsedhodgkinlymphomapatientslongtermresultsofthegeltamogroupbreshapstudy AT lopezj p1083brentuximabvedotinetoposidesolumedrolhighdosearacplatinumfollowedbyhdtapbsctforrefractoryrelapsedhodgkinlymphomapatientslongtermresultsofthegeltamogroupbreshapstudy AT pinanajl p1083brentuximabvedotinetoposidesolumedrolhighdosearacplatinumfollowedbyhdtapbsctforrefractoryrelapsedhodgkinlymphomapatientslongtermresultsofthegeltamogroupbreshapstudy AT bastosm p1083brentuximabvedotinetoposidesolumedrolhighdosearacplatinumfollowedbyhdtapbsctforrefractoryrelapsedhodgkinlymphomapatientslongtermresultsofthegeltamogroupbreshapstudy AT canalesm p1083brentuximabvedotinetoposidesolumedrolhighdosearacplatinumfollowedbyhdtapbsctforrefractoryrelapsedhodgkinlymphomapatientslongtermresultsofthegeltamogroupbreshapstudy AT gutierreza p1083brentuximabvedotinetoposidesolumedrolhighdosearacplatinumfollowedbyhdtapbsctforrefractoryrelapsedhodgkinlymphomapatientslongtermresultsofthegeltamogroupbreshapstudy AT rodriguezsalazarmj p1083brentuximabvedotinetoposidesolumedrolhighdosearacplatinumfollowedbyhdtapbsctforrefractoryrelapsedhodgkinlymphomapatientslongtermresultsofthegeltamogroupbreshapstudy AT navarroa p1083brentuximabvedotinetoposidesolumedrolhighdosearacplatinumfollowedbyhdtapbsctforrefractoryrelapsedhodgkinlymphomapatientslongtermresultsofthegeltamogroupbreshapstudy AT suredaa p1083brentuximabvedotinetoposidesolumedrolhighdosearacplatinumfollowedbyhdtapbsctforrefractoryrelapsedhodgkinlymphomapatientslongtermresultsofthegeltamogroupbreshapstudy |